Search

Author/Creator Cheng, L.

1. 134P Safety and efficacy of multi-target TKI combined with nivolumab in checkpoint inhibitor-refractory advanced NSCLC patients: A prospective, single arm, two stage study. (December 2022)

Authors:
Han, B.; Zhang, B.; Zhong, H.; Shi, C.; Gao, Z.; Zhong, R.; Gu, A.; Chu, T.; Wang, H.; Xiong, L.; Zhang, W.; Zhang, X.; Yan, B.; Teng, J.; Wang, W.; Bai, H.; Qiao, R.; Cheng, L.; Kuang, Y.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 2648 Novel DNA methylation therapeutic targets in urothelial carcinoma (UC) from patients with paired metachronous primary and metastatic tumors. (September 2015)

Authors:
Hahn, N.; Cramer, H.; Badve, S.; Cheng, L.; Gokmen-Polar, Y.; Miller, D.; Buechlein, A.; Rusch, D.; Fang, F.; Frankhouser, D.; Bundschu, R.; Ganbat, J.O.; Foster, R.; Bihrle, R.; Masterson, T.; Gardner, T.; Koch, M.; Marchionni, L.; Pearlly, Y.; Nephew, K.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S529
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗